Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can robotic tools make stomach cancer surgery safer and faster?

NCT ID NCT06881043

Disease control Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This study looks at whether robotic-assisted surgery using a vessel sealer can improve outcomes for people with locally advanced stomach cancer. The vessel sealer is a tool that cuts and seals blood vessels with less heat damage than older devices. Researchers will track 300 patients to see how many have complications within 30 days after surgery, how quickly they recover, and how well the cancer is controlled. The goal is to find out if this approach is safer and more effective than standard laparoscopic surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Robotic-assisted surgery using the Vessel Sealer Extend instrument
What this could lead to
If it works, this could establish robotic surgery with the vessel sealer as a safer, more precise option for advanced gastric cancer, reducing complications and speeding recovery.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by patient selection. The benefits of robotic surgery for advanced gastric cancer remain debated, and complications are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Primary gastric adenocarcinoma at the stage of cT2-4a, N-/+, M0.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from over 18 to under 75 years * Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy * cT2-4a, N-/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition * Preoperative abdominal enhanced CT and lung CT (or PET-CT) showed no distant metastasis * Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale * ASA (American Society of Anesthesiology) class I to III * Written informed consent Exclusion Criteria: * Gastric multiple primary carcinoma or multiple primary cancer * History of previous upper abdominal surgery (except laparoscopic cholecystectomy) * History of previous gastric surgery (except ESD/EMR (Endoscopic Submucosal Dissection/Endoscopic Mucosal Resection ) for gastric cancer) * Preoperative gastric CT evaluation and chest and abdominal imaging evaluation were not performed before surgery, and the clinical stage of the tumor was not comprehensively evaluated * Enlarged or bulky regional lymph node （diameter over 3cm）supported by preoperative imaging * History of other malignant disease within the past 5 years * History of previous neoadjuvant chemotherapy or radiotherapy * History of unstable angina or myocardial infarction within the past 6 months * History of cerebrovascular accident within the past 6 months * History of continuous systematic administration of corticosteroids within 1 month * FEV1\<50% of the predicted values * Women during pregnancy or breast-feeding * Severe mental disorder * Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer * Preoperative evaluation requires combined organ resection * Requirement of simultaneous surgery for other disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system disorder digestive system neoplasm Digestive System Neoplasms gastric adenocarcinoma gastric cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric adenocarcinoma Locally advanced gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.